Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898926 | 0.88 | MAPT (0.52) | MAPTGAANOTUMPTPN5HTR2C | |
| SCHEMBL13454078 | 0.81 | GAA (0.44) | MAPTGAANOTUMPTPN5TAS2R14 | |
| SCHEMBL15516662 | 0.79 | NOTUM (0.46) | NOTUMP2RX4P2RX7ACP1PTPN5 | |
| SCHEMBL5329450 | 0.78 | MAPT (0.57) | MAPTGAAHTR2CTP53RECQL | |
| SCHEMBL13454046 | 0.77 | GAA (0.41) | MAPTGAANOTUM | |
| SCHEMBL15517168 | 0.76 | NOTUM (0.41) | NOTUMP2RX4P2RX7ACP1PTPN5 | |
| SCHEMBL12676374 | 0.76 | GAA (0.56) | MAPTGAANOTUMPTPN5TP53 | |
| SCHEMBL12676364 | 0.75 | HTR2C (0.55) | MAPTGAAHTR2C | |
| SCHEMBL12676292 | 0.75 | GAA (0.42) | MAPTGAANOTUMTDP1 | |
| SCHEMBL12676291 | 0.75 | GAA (0.46) | MAPTGAANOTUMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593069-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2016-02-11 | — | — | US | disclosed |
| US-9162968-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2014-12-18 | — | — | US | disclosed |
| US-8722939-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2011059821-A2 | CYCLOHEXANE-1,3-DIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885NOTUM 1604/4885 |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885NOTUM 1604/4885 |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885NOTUM 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.